Rupert Vessey, Bristol Myers Squibb president of research and early development (BMS)

Bris­tol My­ers hun­kers down at the deals ta­ble, ex­e­cut­ing a new I/O play in biotech buy­out

A week af­ter Bris­tol My­ers Squibb plunked down $475 mil­lion up­front to part­ner with Drag­on­fly on an IL-12 pro­gram — which fits neat­ly in­to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.